The last mile: translational research to improve CKD outcomes

Delphine S. Tuot, Due to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Clarissa Jonas Diamantidis, Due to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Cynthia F. Corbett, Due to the number of contributing authors, the affiliations are provided in the Supplemental Material.
L Ebony Boulware, Due to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Chester H. Fox, Due to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Donna H. Harwood, Due to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Robert A. Star, Due to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Krystyna E. Rys-Sikora, Due to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Andrew Narva, Due to the number of contributing authors, the affiliations are provided in the Supplemental Material. narvaa@niddk.nih.gov.

Abstract

The National Institute of Diabetes and Digestive and Kidney Diseases-supported Kidney Research National Dialogue asked the scientific community to formulate and prioritize research objectives that would enhance understanding of kidney function and disease and improve clinical outcomes. An engaged and growing group of investigators working in type 2 translation (from clinical evidence to implementation in the community) identified barriers to improving patient care in CKD and suggested research priorities to test translational strategies that have been effective for other chronic diseases.